Cempra, Inc. (CEMP)
(Delayed Data from NSDQ)
$2.33 USD
+0.03 (1.09%)
Updated Nov 3, 2017 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Melinta Therapeutics, Inc. [CEMP]
Reports for Purchase
Showing records 81 - 89 ( 89 total )
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
We initiate coverage with a Buy rating and $35 price target.
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Initiating coverage - New Antibiotics: Resistance is Futile
Provider: G.RESEARCH, LLC
Analyst: KEDRA K